MicuRx
MicuRx is a global biopharmaceutical company committed to discovering, developing, and delivering innovative medicines that address unmet clinical needs, especially in the field of infectious diseases and antibiotic resistance. Founded in 2007, the company focuses on novel drug design, clinical development, and commercialization of antibiotics and other therapeutics, with a strong emphasis on combating drug-resistant bacteria and unmet medical needs.
Industries
Nr. of Employees
small (1-50)
MicuRx
Products
Oxazolidinone antibiotic, oral formulation (approved in China)
An orally administered oxazolidinone-class antibiotic approved for complicated skin and soft tissue infections; clinical expansion studies (pediatric) and international trials ongoing.
Water‑soluble injectable prodrug for oxazolidinone (IV-to-oral sequential therapy)
A water‑soluble injectable prodrug that converts in vivo to the active oxazolidinone for IV administration, intended for sequential IV-to-oral therapy in complex infections.
Next‑generation polymyxin‑class antibiotic (systemic and inhaled exploration)
A polymyxin-class antibiotic scaffold engineered to retain bactericidal activity against multidrug-resistant Gram-negative pathogens while aiming to reduce nephrotoxicity and neurotoxicity; inhalation formulations explored for pulmonary infections.
Oral boron/benzazole-containing antibiotic candidate for NTM infections
An orally available small-molecule antibiotic candidate developed for nontuberculous mycobacterial (NTM) pulmonary disease with demonstrated preclinical and Phase I human data supporting safety and PK.
Kidney‑targeted small-molecule therapies (preclinical)
Novel drug candidates designed to increase local renal exposure to improve efficacy and reduce systemic toxicity for kidney indications.
Next‑generation tumor‑targeting ADC (preclinical)
A next‑generation antibody–drug conjugate program featuring an optimized cytotoxic payload and linker chemistry for oncology indications in preclinical development.
Oxazolidinone antibiotic, oral formulation (approved in China)
An orally administered oxazolidinone-class antibiotic approved for complicated skin and soft tissue infections; clinical expansion studies (pediatric) and international trials ongoing.
Water‑soluble injectable prodrug for oxazolidinone (IV-to-oral sequential therapy)
A water‑soluble injectable prodrug that converts in vivo to the active oxazolidinone for IV administration, intended for sequential IV-to-oral therapy in complex infections.
Next‑generation polymyxin‑class antibiotic (systemic and inhaled exploration)
A polymyxin-class antibiotic scaffold engineered to retain bactericidal activity against multidrug-resistant Gram-negative pathogens while aiming to reduce nephrotoxicity and neurotoxicity; inhalation formulations explored for pulmonary infections.
Oral boron/benzazole-containing antibiotic candidate for NTM infections
An orally available small-molecule antibiotic candidate developed for nontuberculous mycobacterial (NTM) pulmonary disease with demonstrated preclinical and Phase I human data supporting safety and PK.
Kidney‑targeted small-molecule therapies (preclinical)
Novel drug candidates designed to increase local renal exposure to improve efficacy and reduce systemic toxicity for kidney indications.
Next‑generation tumor‑targeting ADC (preclinical)
A next‑generation antibody–drug conjugate program featuring an optimized cytotoxic payload and linker chemistry for oncology indications in preclinical development.
Services
Design and conduct of global multicenter Phase I–III trials including randomized, double-blind and dose-escalation study designs.
In vitro susceptibility testing, resistance frequency assessment, and in vivo infection model studies plus nonclinical toxicology in standard species.
Development of oral tablets, water‑soluble injectable prodrugs, and inhalation formulations with associated manufacturing management and CMC planning.
Preparation and management of regulatory filings and engagement with major regulators, including strategy to obtain expedited designations.
Preparation of manuscripts and presentation of clinical and preclinical data at international scientific conferences.
Clinical safety assessment processes and mechanisms for adverse event reporting and pharmacovigilance.
Design and conduct of global multicenter Phase I–III trials including randomized, double-blind and dose-escalation study designs.
In vitro susceptibility testing, resistance frequency assessment, and in vivo infection model studies plus nonclinical toxicology in standard species.
Development of oral tablets, water‑soluble injectable prodrugs, and inhalation formulations with associated manufacturing management and CMC planning.
Preparation and management of regulatory filings and engagement with major regulators, including strategy to obtain expedited designations.
Preparation of manuscripts and presentation of clinical and preclinical data at international scientific conferences.
Clinical safety assessment processes and mechanisms for adverse event reporting and pharmacovigilance.
Expertise Areas
- Antibiotic discovery and development
- Antimicrobial resistance research
- Clinical trial management (Phase I–III)
- Formulation development (oral, IV, inhalation)
Key Technologies
- Medicinal chemistry for antibiotics
- Prodrug design
- Oral and intravenous formulation development
- Inhalation/nebulized delivery
News & Updates
MicuRx will present 15 research datasets related to its pipeline products, focusing on Contezolid and MRX-5, at the ESCMID Global 2025 conference in Vienna.
The clinical trial of MRX-4 for injection transitioning to oral Contezolid tablets for treating skin and soft tissue infections in China has achieved its primary efficacy endpoint.
A study led by Johns Hopkins University demonstrated MRX-5's efficacy against M. abscessus in a mouse model, showing potential as a new treatment for NTM infections.
Research on MRX-5 and MRX-8 presented at the conference supports their potential in treating NTM lung disease and Pseudomonas aeruginosa infections.
The FDA granted QIDP and Fast Track designations for Contezolid and MRX-4 for treating diabetic foot infections, facilitating faster approval.
An overview of the global challenge of bacterial resistance to antibiotics and MicuRx's efforts in developing new antibiotics.
MicuRx will present 15 research datasets related to its pipeline products, focusing on Contezolid and MRX-5, at the ESCMID Global 2025 conference in Vienna.
The clinical trial of MRX-4 for injection transitioning to oral Contezolid tablets for treating skin and soft tissue infections in China has achieved its primary efficacy endpoint.
A study led by Johns Hopkins University demonstrated MRX-5's efficacy against M. abscessus in a mouse model, showing potential as a new treatment for NTM infections.
Research on MRX-5 and MRX-8 presented at the conference supports their potential in treating NTM lung disease and Pseudomonas aeruginosa infections.
The FDA granted QIDP and Fast Track designations for Contezolid and MRX-4 for treating diabetic foot infections, facilitating faster approval.
An overview of the global challenge of bacterial resistance to antibiotics and MicuRx's efforts in developing new antibiotics.